• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Choueiri on adjuvant pembrolizumab for high-risk RCC at 30-month follow up

Video

“These are consistent results that continue to demonstrate a disease-free survival benefit of pembrolizumab adjuvant versus placebo,” says Toni K. Choueiri, MD.

In this video, Toni K. Choueiri, MD, discusses the background, findings, and takeaways of the study, “Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Choueiri is a professor of medicine at Harvard Medical School, and an attending physician, director of the Genitourinary Oncology Disease Center, and director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts.

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.